Brentuximab Vedotin

• A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral… Pending
  2024-511567-28-01 Phase II 1 country Kooperativni Lymfomova Skupina z.s.
• BeCALM - Brentuximab vedotin in CutAneous T-cell Lymphomas (CTCL): post-allogeneic hematopoietic stem cell transplant Maintenance Pending
  2025-521093-34-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) Pending
  2026-525263-41-00 Phase III 1 country Polska Grupa Badawcza Chloniakow
• Pembro-FLASH Recruiting
  2022-501458-13-01 Phase II 1 country University Of Cologne
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl… Recruiting
  2022-500031-37-00 Phase III 7 countries University College London
• Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting
  2022-501710-62-02 Phase IV 2 countries Lysarc
• A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Ref… Ended
  2024-516149-38-00 Phase II 4 countries Fundacion Geltamo
• Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended
  2023-503384-41-00 Phase III 7 countries Seagen Inc.
• A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab… Ended
  2024-520123-83-01 Phase II 1 country Universita' Degli Studi Di Perugia
• EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study Ended
  2023-508478-27-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer
• Transplant BRaVE NHL: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse… Ended
  2023-510556-22-00 Phase II 3 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• Brentuximab vedotin+Adriamycin, vinblastine, and dacarbazine in pediatric patients with advanced stage newly diagnosed Hodgkin lymphoma Ended
  2023-506415-18-00 Phase I/II 1 country Takeda Development Center Americas Inc.
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Ended
  2023-503387-16-00 Phase II 4 countries Seagen Inc.
• A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cel… Ended
  2023-509155-14-00 Phase II 3 countries Seagen Inc.
• HD21 Ended
  2024-518022-33-00 Phase III 6 countries University Of Cologne
• A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractor… Ended
  2022-500400-22-00 Phase III 6 countries Merck Sharp & Dohme LLC
• Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Ended
  2023-506419-16-00 Phase III 9 countries Takeda Development Center Americas Inc.

Showing 1–17 of 17 trials